Ascelia Pharma - Update on Q2 2024 and rights issue

You can already now sign up for the event and send in your questions. You don’t have to participate live to send in questions for the event.

Meet and ask questions to Deputy CEO Julie Waras Brogren from Ascelia Pharma on 19 August 2024 at 2:30 PM CEST.

During Q2 Ascelia Pharma announced very strong headline data from the Orviglance phase 3 study and draws down the second tranche on the existing loan facility with Fenja Capital. After the quarter closed the company announced a planned rights issue of gross SEK 105 mio.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. Ascelia Pharma develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE)

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 11 July 11.41 AM.